2023 - Research.com Medicine in Netherlands Leader Award
Pieter Sonneveld merges Internal medicine with Pediatrics in his research. He performs integrative Pediatrics and Internal medicine research in his work. Pieter Sonneveld connects Oncology with Cancer research in his study. Borrowing concepts from Leukemia, he weaves in ideas under Cancer research. His study deals with a combination of Leukemia and Myeloid leukemia. His Myeloid leukemia study frequently links to related topics such as Immunology. His Daunorubicin research extends to the thematically linked field of Immunology. He performs multidisciplinary study on Chemotherapy and Bortezomib in his works. Pieter Sonneveld performs multidisciplinary study on Multiple myeloma and Thalidomide in his works.
His work on Genetics as part of general Gene research is frequently linked to Cancer research, thereby connecting diverse disciplines of science. He performs integrative study on Genetics and Gene in his works. Pieter Sonneveld integrates Cancer research and Leukemia in his research. His Internal medicine research includes a combination of various areas of study, such as Oncology, Surgery, Gastroenterology and Intensive care medicine. Pieter Sonneveld merges many fields, such as Oncology and Chemotherapy, in his writings. Pieter Sonneveld merges Surgery with Chemotherapy in his research. He integrates Gastroenterology with Internal medicine in his study. His Multiple myeloma study is within the categories of Bortezomib, Lenalidomide and Thalidomide. Many of his studies on Immunology involve topics that are commonly interrelated, such as Leukemia.
Pieter Sonneveld is doing genetic studies as part of his Gene expression profiling and Gene signature and Gene expression investigations. His Multiple myeloma study frequently draws connections to adjacent fields such as Immunology. His research on Immunology often connects related topics like Multiple myeloma. His Internal medicine study frequently draws connections to other fields, such as Obesity. His Obesity study frequently intersects with other fields, such as Internal medicine. He connects Oncology with Intensive care medicine in his research. While working in this field, Pieter Sonneveld studies both Intensive care medicine and Oncology. His Gene study frequently draws parallels with other fields, such as Regulator. His Regulator study typically links adjacent topics like Gene.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International staging system for multiple myeloma.
Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley.
Journal of Clinical Oncology (2005)
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
T Philip;C Guglielmi;A Hagenbeek;R Somers.
The New England Journal of Medicine (1995)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka.
The New England Journal of Medicine (2016)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson.
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: